Evaluation of the effect of oral Dydrogesterone (Duphaston) in threatened abortion at first trimester

Evaluation of the effect of oral Dydrogesterone (Duphaston) on vaginal bleeding and abortion rate in threatened abortion at first trimester

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120918010876N5

Enrollment

170

Registered

2018-02-04

Start date

2017-11-21

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Threatened abortion. Threatened abortion

Interventions

Intervention 1: Intervention group: Treatment with oral dyrogesterone (Duphaston®, Solvay company, USA), 40 mg in the first dose, followed by 10 mg every eight hours until the bleeding was discontinue

Eligibility

Sex/Gender

Female

Age

18 Years to 35 Years

Inclusion criteria

Inclusion criteria: Pregnant women in the first trimester Presence of symptoms and signs of threatened abortion Singleton pregnancy Having an ultrasound report with viable fetus

Exclusion criteria

Exclusion criteria: The presence of underlying illnesses such as high blood pressure, diabetes Known allergy to dystrogesterone components

Design outcomes

Primary

Measure	Time frame
Abortion. Timepoint: Daily check from the beginning of the study up to 20 weeks. Method of measurement: Observation and clinical symptoms.;Vaginal bleeding. Timepoint: At the beginning of the study and after starting the study until the end of the study. Method of measurement: Amount and number of sanitary pads.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Masoome Mirzamoradi

Shahid Beheshti University of Medical Sciences

drmoradi000@yahoo.com+98 21 5506 6263

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026